down arrow

Safeguard Scientifics, Inc.

  • Market Cap: N/A
  • Industry: Capital Markets
  • ISIN: US7864493066
USD
0.74
-0.01 (-1.65%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.740.75

52 Week

0.650.99
Valuation
Technical
Day's Volume

CASH

30.19 k

Shareholding (Mar 2025)

FII

0.73%

Held by 6 FIIs

DII

93.68%

Held by 6 DIIs

Promoter

0.00%

What does Safeguard Scientifics, Inc. do?

22-Jun-2025

Safeguard Scientifics, Inc. provides capital to technology companies in healthcare, financial services, and digital media, with a market capitalization of $13.66 million. The company reported a net profit loss of $1 million as of March 2025.

Overview:<BR>Safeguard Scientifics, Inc. is engaged in providing capital to technology companies within the fields of healthcare, financial services, and digital media, operating in the Capital Markets industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 13.66 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -999,999.00<BR>- Return on Equity: -100.85%<BR>- Price to Book: 1.51<BR><BR>Contact Details:<BR>- Address: 150 NORTH RADNOR-CHESTER ROAD, SUITE F-200 RADNOR PA : 19087<BR>- Tel: ['1 610 2930600', '1 610 9754913']<BR>- Fax: 1 610 2930601<BR>- Website: http://www.safeguard.com/

Read More

Who are in the management team of Safeguard Scientifics, Inc.?

22-Jun-2025

As of March 2022, the management team of Safeguard Scientifics, Inc. includes Dr. Robert Rosenthal as Chairman of the Board, along with independent directors Mr. Russell Glass, Mr. Joseph Manko, and Ms. Maureen Morrison.

As of March 2022, the management team of Safeguard Scientifics, Inc. includes Dr. Robert Rosenthal, who serves as the Chairman of the Board. Additionally, the board consists of independent directors: Mr. Russell Glass, Mr. Joseph Manko, and Ms. Maureen Morrison.

Read More

Is Safeguard Scientifics, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data available for Safeguard Scientifics, Inc. to assess its current stance.

As of 1 October 2023, the technical data for Safeguard Scientifics, Inc. is insufficient to form a view on its current stance.

Read More

Is Safeguard Scientifics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Safeguard Scientifics, Inc. is rated as attractive due to its undervaluation, evidenced by a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.5, and a return on equity of 12%, which are lower than peers like BioScrip and Acorda Therapeutics, while also outperforming the Sensex.

As of 1 October 2023, Safeguard Scientifics, Inc. has moved from a fair to an attractive rating. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.5, and a return on equity of 12%. <BR><BR>In comparison to its peers, such as BioScrip, Inc. with a price-to-earnings ratio of 18.5 and Acorda Therapeutics, Inc. at 16.0, Safeguard's lower valuation suggests it is trading at a discount relative to the market. Additionally, the stock's recent performance has outpaced the Sensex, reinforcing the notion of undervaluation.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Capital Markets

stock-summary
Market cap

USD 14 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

-100.85%

stock-summary
Price to Book

1.51

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.13%
0%
-5.13%
6 Months
-10.82%
0%
-10.82%
1 Year
-20.77%
0%
-20.77%
2 Years
-25.24%
0%
-25.24%
3 Years
-77.3%
0%
-77.3%
4 Years
-89.58%
0%
-89.58%
5 Years
-88.67%
0%
-88.67%

Safeguard Scientifics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-176.52%
EBIT to Interest (avg)
-3.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.01%
ROCE (avg)
0
ROE (avg)
83.48%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.54
EV to EBIT
-3.72
EV to EBITDA
-4.49
EV to Capital Employed
2.54
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-68.35%
ROE (Latest)
-100.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (5.59%)

Foreign Institutions

Held by 6 Foreign Institutions (0.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 60.00% vs 42.86% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.50",
          "val2": "-1.00",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-2.00",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.12% vs 31.47% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-5.40",
          "chgp": "57.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "0.80",
          "chgp": "-700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-9.80",
          "chgp": "-6.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.50
-1.00
50.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.80
-2.00
60.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 60.00% vs 42.86% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.30
-5.40
57.41%
Interest
0.00
0.00
Exceptional Items
-4.80
0.80
-700.00%
Consolidate Net Profit
-10.40
-9.80
-6.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.12% vs 31.47% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Safeguard Scientifics, Inc. stock-summary
stock-summary
Safeguard Scientifics, Inc.
Capital Markets
Safeguard Scientifics, Inc. is engaged in providing capital to technology companies within the fields of healthcare, financial services and digital media. The Company holds interest in companies, which it refers to as partner companies. As of December 31, 2016, the Company held interests in 29 non-consolidated partner companies. The Company offers operational and management support to each of its partner companies. In addition to management and operational support, the Company offers ongoing planning and development assessment. It provides mentoring, advice and guidance to develop partner company management. The Company serves on the boards of directors of its partner companies, working with them to develop and implement strategic and operating plans. It measures and monitors achievement of these plans through regular review of operational and financial performance measurements.
Company Coordinates stock-summary
Company Details
150 NORTH RADNOR-CHESTER ROAD, SUITE F-200 RADNOR PA : 19087
stock-summary
Tel: 1 610 29306001 610 9754913
stock-summary
http://www.safeguard.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."